注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Eloxx Pharmaceuticals Inc是一家临床阶段的生物制药公司。该公司专注于核糖体调节,利用其TURBO-ZM化学技术平台及其氨基糖苷库开发口服小分子核糖体调节剂(RMA)和真核核糖体选择性糖苷(ERSG),用于治疗罕见和极罕见的过早终止密码子疾病和核糖体突变。该公司的主要候选产品ELX-02是一种小分子,旨在恢复全长功能蛋白的生产。ELX-02是一种基于氨基糖苷类抗生素(如庆大霉素)设计的研究性ERSG,对真核核糖体具有更高的选择性。该公司的临床前项目侧重于选择罕见疾病,包括遗传性疾病、由无义突变引起的癌症、肾脏疾病,包括常染色体显性多囊肾病,以及罕见的眼部遗传疾病。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Sudhir Kumar | - | 2018 | Member of Scientific Advisory Board |
Steven D. Rubin | 64 | 2017 | Independent Director |
Rachel Green | - | 2018 | Member of Scientific Advisory Board |
David Bedwell | - | 2018 | Member of Scientific Advisory Board |
Sumit Aggarwal | 51 | 2021 | President, CEO & Director |
Patrick A. Flume | - | - | Member of Medical Advisory Board |
Timor Baasov | - | - | Member of Scientific Advisory Board |
Alan Edmund Walts | 63 | 2021 | Independent Director |
Donald Vandevanter | - | - | Member of Medical Advisory Board |
Lindsay Androski | 52 | 2022 | Independent Director |
Lynne Elizabeth Maquat | - | 2018 | Member of Scientific Advisory Board |
Christiane De Boeck | - | - | Member of Medical Advisory Board |
Noreen Roth Henig | 59 | - | Member of Medical Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核